Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report

BACKGROUND: Crizotinib is recommended as first-line therapy in ROS1-driven lung adenocarcinoma. However, the optimal first-line therapy for this subgroup of lung cancer is controversial according to the available clinical data. CASE PRESENTATION: Here, we describe a 57-year-old man who was diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Liang, Xia, Jingwen, Zhang, Jing, Zhang, Yuanyuan, Zhu, Ning, Zhang, Peng, Zhang, Youzhi, Zhang, Xiujuan, Li, Shengqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781300/
https://www.ncbi.nlm.nih.gov/pubmed/29361925
http://dx.doi.org/10.1186/s12890-018-0585-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5781300/
https://www.ncbi.nlm.nih.gov/pubmed/29361925
http://dx.doi.org/10.1186/s12890-018-0585-9

Ejemplares similares